Atlas Trials

A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine

Clinical trial NCT03854110 · RECRUITING

Trial details

NCT number
NCT03854110
Sponsor
Persevere Therapeutics Inc.
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Ovarian Cancer
Start date
2019-01-14
Primary completion
2027-07-31
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.